Healios K.K.
Healios K.K. (HLOSF) Financial Performance & Income Statement Overview
Explore the financials of Healios K.K. (HLOSF), including yearly and quarterly data on income, cash flow, and balance sheets.
Healios K.K. (HLOSF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Healios K.K. HLOSF financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $18.00M | $34.00M | $498.00M | $10.00M |
| Cost of Revenue | $30.00M | $30.00M | $68.00M | $73.00M |
| Gross Profit | -$12.00M | $4.00M | $430.00M | -$63.00M |
| Gross Profit Ratio | -$0.67 | $0.12 | $0.86 | -$6.30 |
| R&D Expenses | $486.00M | $355.00M | $436.00M | $683.00M |
| SG&A Expenses | $372.00M | $313.00M | $315.00M | $301.00M |
| Operating Expenses | $858.00M | $668.00M | $751.00M | $984.00M |
| Total Costs & Expenses | $888.00M | $698.00M | $819.00M | $1.06B |
| Interest Income | $0.00 | $0.00 | $160.00M | $303.00M |
| Interest Expense | $0.00 | $0.00 | $335.00M | $1.76B |
| Depreciation & Amortization | $80.00M | $72.00M | $72.00M | $73.00M |
| EBITDA | -$786.00M | -$573.00M | -$50.00M | -$673.00M |
| EBITDA Ratio | -$43.67 | -$16.85 | -$0.10 | -$67.30 |
| Operating Income | -$870.00M | -$664.00M | -$321.00M | -$1.05B |
| Operating Income Ratio | -$48.33 | -$19.53 | -$0.64 | -$104.70 |
| Other Income/Expenses (Net) | $1.31B | -$872.00M | -$136.00M | -$1.46B |
| Income Before Tax | $443.00M | -$1.54B | -$457.00M | -$2.51B |
| Income Before Tax Ratio | $24.61 | -$45.18 | -$0.92 | -$251.10 |
| Income Tax Expense | $195.00M | $12.00M | $73.00M | -$91.00M |
| Net Income | $256.00M | -$1.53B | -$534.00M | -$2.42B |
| Net Income Ratio | $14.22 | -$45.09 | -$1.07 | -$242.50 |
| EPS | $2.84 | -$17.00 | -$5.92 | -$29.06 |
| Diluted EPS | $2.84 | -$17.00 | -$5.92 | -$29.06 |
| Weighted Avg Shares Outstanding | $90.19M | $90.15M | $90.20M | $83.45M |
| Weighted Avg Shares Outstanding (Diluted) | $90.19M | $90.15M | $90.13M | $83.45M |
Over the past four quarters, Healios K.K. demonstrated steady revenue growth, increasing from $10.00M in Q1 2024 to $18.00M in Q4 2024. Operating income reached -$870.00M in Q4 2024, maintaining a consistent -4833% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$786.00M, reflecting operational efficiency. Net income rose to $256.00M, with EPS at $2.84. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan